Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00554853 · ClinicalTrials.gov registry record · Phase 3
PPAR-gamma Agonists, Rheumatoid Arthritis and Cardiovascular Disease
A Phase 3 study, sponsored by University of Michigan.
- Completed
- Registry status
- Phase 3
- Development phase
- 143
- Enrollment target
NCT00554853 is a Phase 3 study that has completed, run by University of Michigan. The registered enrollment target is 143 participants.
The verdict
NCT00554853, a Phase 3 study, has completed, sponsored by University of Michigan.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 143 participants
- Enrollment target
Study Summary
Patients with rheumatoid arthritis have a significantly higher risk to develop heart attacks and other complications of their blood vessels. New therapies are needed to prevent this complication. The purpose of this study is to establish the role of the medication pioglitazone in improving the function of the blood vessels and heart and decreasing the risk of future atherosclerosis development in individuals with rheumatoid arthritis. As a secondary aim-point, we will evaluate the efficacy of pioglitazone in improving rheumatoid arthritis disease activity and markers of inflammation.
Interventions
- DRUG pioglitazone
- DRUG Sublingual nitroglycerine
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 143 participants |
| Start Date | 2007-11 |
| Est. Completion | 2013-01 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00554853
The ClinicalTrials.gov registry entry for NCT00554853 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 143 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of Michigan, which has 1,327 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which pioglitazone is the first listed.
NCT00554853 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00554853 about?
NCT00554853 is a clinical study titled "PPAR-gamma Agonists, Rheumatoid Arthritis and Cardiovascular Disease". Patients with rheumatoid arthritis have a significantly higher risk to develop heart attacks and other complications of their blood vessels. New therapies are needed to prevent this complication. The purpose of this study is to establish the role of the medication pioglitazone in improving the funct...
What is the current status of trial NCT00554853?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 143 participants. The study started on 2007-11. Estimated completion is 2013-01.
What interventions are being tested in trial NCT00554853?
The interventions under investigation include: pioglitazone (DRUG), Sublingual nitroglycerine (DRUG).
Who is sponsoring clinical trial NCT00554853?
This trial is sponsored by University of Michigan, which has 1,327 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.